Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 30, 2026 09:00 ET | Source: InnSight Technology Inc.

Richard King Mellon Foundation Awards $515,000 Social Impact Investment to InnSight Technology Following First-Place SII Pitch Competition Win

InnSight Technology announced a $515,000 Social Impact Investment from the Richard King Mellon Foundation.
July 29, 2026 10:46 ET | Source: Spherix Global Insights

New Cross-Study Analysis from Spherix Global Insights Combines Physician, Dietitian and Patient Chart Data to Show Access Barriers Still Curbing Xphozah Uptake Ahead of the TDAPA Cliff

Exton, PA, July 29, 2026 (GLOBE NEWSWIRE) -- Access, not efficacy, stands between Ardelyx's Xphozah® (tenapanor) and a materially larger share of the dialysis hyperphosphatemia market, according to...
July 28, 2026 08:00 ET | Source: Claris Bio

Claris Bio Unveils Development Strategy, Planned Pivotal Study Supported by $118 Million Series B Financing from Top-Tier Investors, and Multiple Leadership Appointments

Positive proof-of-concept clinical data show substantial improvements in visual acuity in limbal stem cell deficiency (LSCD) patients treated with CSB-001 Pivotal studies for CSB-001 in LSCD planned...
July 28, 2026 08:00 ET | Source: YD Bio Limited

YD Bio Launches Cross-Border Cancer Testing Pilot with Numia Health to Evaluate Expanded Access to Molecular Diagnostics in Canada

The six-month pilot is designed to evaluate the potential scalability of bringing physician-ordered, blood-based OkaiDx laboratory-developed tests to patients in Canada Taipei, Taiwan, July 28, 2026...
July 24, 2026 14:40 ET | Source: Outlook Therapeutics, Inc.

Outlook Therapeutics Announces LYTENAVA™ FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMD

Landmark FDA Approval Is an Important Milestone in Retina Care, Bringing Patients and Physicians an Ophthalmic Bevacizumab Developed Specifically for the Eye Following Years of Rigorous Clinical and...
July 24, 2026 10:41 ET | Source: Research and Markets

Electrosurgery Market Projected to Reach $11.59 Billion by 2031 as Demand for Minimally Invasive Procedures Rises - Analysis by Product, Surgery, End User and Region

Dublin, July 24, 2026 (GLOBE NEWSWIRE) -- The "Electrosurgery Market by Product, Surgery, End User: Global Forecast to 2031" has been added to ResearchAndMarkets.com's offering.The global...
July 24, 2026 09:11 ET | Source: Spherix Global Insights

Subcutaneous PD-1 Inhibitors Transition from Novelty to Routine Care as Oncologists Tailor Use by Tumor Type, According to Spherix Global Insights

Exton, PA, July 24, 2026 (GLOBE NEWSWIRE) -- The U.S. market for PD-1 inhibitors has entered a new phase of evolution. According to the latest RealTime Dynamix™: PD-1 Inhibition in Solid Tumors...
July 24, 2026 06:50 ET | Source: ANI Pharmaceuticals, Inc.

ANI Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 7, 2026 at 8:00 a.m. ET

PRINCETON, N.J., July 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that the Company will release its second quarter 2026 financial...
July 24, 2026 06:15 ET | Source: F. Hoffmann-La Roche Ltd

CHMP recommends EU approval of Roche’s Susvimo, the first continuous delivery treatment for neovascular age-related macular degeneration (nAMD)

Susvimo is the first and only continuous delivery treatment that offers an alternative to standard of care eye injections for nAMDPositive recommendation is based on data from the LADDER, Archway and...
July 23, 2026 14:04 ET | Source: Spherix Global Insights

Sotyktu Begins Defining a New Oral Treatment Segment in Psoriatic Arthritis, According to Spherix Global Insights Launch Research

Exton, PA, July 23, 2026 (GLOBE NEWSWIRE) -- The launch of Bristol Myers Squibb's Sotyktu® (deucravacitinib) is doing more than introducing another treatment option for psoriatic arthritis (PsA), it...